| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.17 | 6e-09 |
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | 0.19 | 1e-08 |
| mRNA | WZ3105 | GDSC1000 | pan-cancer | AAC | 0.17 | 2e-08 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | 0.18 | 3e-08 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | 0.17 | 5e-08 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | 0.17 | 5e-08 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.17 | 1e-07 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.16 | 1e-07 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-07 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.15 | 2e-07 |